News for BIOGEN INC (BIIBCL.SN)

Summary On July 25, 2025, Biogen Inc (BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. ( BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Me

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on t

Summary Biogen Inc (BIIB) has announced its participation in the 2025 Alzheimer's Association International Conference (AAIC) from July 27-31 in Toronto, Canada

Biogen Inc.

Biogen (BIIB) plans to enhance its manufacturing capabilities with a substantial $2 billion investment in North Carolina's Research Triangle Park (RTP). This ne

Investment builds on Biogen's 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025

Truist has revised its outlook on Biogen (BIIB), lowering its rating from "Buy" to "Hold" and cutting its price target to $142 from the previous $199. This chan

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) - today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the company’s pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen’s late-stage clinical pipeline.

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren's, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings de

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and execution of late-stage programs CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.

During the second quarter of 2025, the Patient Opportunity Equity Strategy generated a total return of 15.3% net of fees. Read more here.

Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while […]

Biogen (BIIB) and Stoke Therapeutics presented new data for zorevunersen, showing improvements in cognition and behavior at Week 68 in Dravet syndrome patien

Quick Highlights: Biogen (BIIB) is facing a significant $46 million charge that will impact Q2 2023 earnings. Analysts project potential upside with a 30

Market Analysis by covering: Biogen Inc, Supernus Pharmaceuticals Inc, SAGE Therapeutics Inc. Read 's Market Analysis on Investing.com

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen - two 50 mg doses 14 days apart - and a higher maintenance regimen - 28 mg every four months.

RBC Capital analyst Brian Abrahams has reiterated his "Outperform" rating for Biogen (BIIB), maintaining the price target at $213. This decision underscores con